The trademark application BRIUMVI was filed by TG Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on June 21, 2021, and it was registered by office on September 28, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Partial Surrender of the trademark registration was recorded on November 14, 2021. Appointment and Replacement of representative of the trademark registration was recorded on January 10, 2023. Licences granted of the trademark registration was recorded on July 16, 2024.